Related Experiment Videos
A radioimmunoassay for prostatic acid phosphatase
National Cancer Institute Monograph
|December 1, 1978
Summary
A new radioimmunoassay for human prostatic acid phosphatase (HPAP) shows greater sensitivity than enzymatic tests. This method accurately stages prostate cancer, offering improved diagnostic potential.
Area of Science:
- Biochemistry
- Oncology
- Immunology
Background:
- Prostate cancer diagnosis relies on accurate staging.
- Current enzymatic methods for human prostatic acid phosphatase (HPAP) have limitations in sensitivity and staging accuracy.
- Novel diagnostic tools are needed for precise prostate cancer classification.
Purpose of the Study:
- To evaluate the diagnostic performance of a solid phase radioimmunoassay for HPAP.
- To compare the sensitivity and staging accuracy of the radioimmunoassay against a standard enzymatic method.
- To assess the clinical potential of the radioimmunochemical approach in prostate cancer diagnosis.
Main Methods:
- Development of a solid phase radioimmunoassay for HPAP.
- Measurement of HPAP levels in patient samples.
- Comparison of staging accuracy between the radioimmunoassay and a p-nitrophenylphosphate-based enzymatic assay.
Main Results:
- The radioimmunoassay demonstrated significantly higher biochemical sensitivity compared to the enzymatic method.
- The radioimmunochemical approach accurately classified 43% of Stage I-II and 94% of Stage III-IV prostate cancers.
- The standard enzymatic method correctly classified only 9% of Stage I-II and 46% of Stage III-IV prostate cancers.
Conclusions:
- The radioimmunoassay for HPAP offers superior sensitivity and staging accuracy for prostate cancer.
- This radioimmunochemical method shows significant potential for improving clinical diagnosis of prostate cancer.
- Further validation of the radioimmunoassay could enhance patient stratification and treatment planning.